HC Wainwright & Co. Maintains Buy on Purple Biotech, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has maintained a Buy rating on Purple Biotech (NASDAQ:PPBT) and increased the price target from $9 to $10.
November 21, 2023 | 6:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Purple Biotech and raised the price target to $10, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals confidence in the company's future performance and can lead to increased investor interest and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100